An Assessment of Herpesvirus Co-infections in Patients with CMV Disease: Correlation with Clinical and Virologic Outcomes

Autor: A, Humar, A, Asberg, D, Kumar, A, Hartmann, G, Moussa, A, Jardine, H, Rollag, H, Mouas, C G, Gahlemann, M D, Pescovitz, Michael, Zakliczynsk
Rok vydání: 2009
Předmět:
Human cytomegalovirus
Herpesvirus 6
Human

viruses
Cytomegalovirus
Herpesvirus 7
Human

medicine.disease_cause
Polymerase Chain Reaction
Gastroenterology
Cohort Studies
Postoperative Complications
Valganciclovir
Immunology and Allergy
Medicine
Pharmacology (medical)
Prospective Studies
biology
Incidence
virus diseases
Middle Aged
Viral Load
Treatment Outcome
Cytomegalovirus Infections
Human herpesvirus 6
Viral disease
Viral load
medicine.drug
Adult
Ganciclovir
medicine.medical_specialty
Adolescent
Roseolovirus Infections
Antiviral Agents
Young Adult
Betaherpesvirinae
Internal medicine
Humans
Aged
Transplantation
business.industry
International Agencies
Organ Transplantation
biochemical phenomena
metabolism
and nutrition

medicine.disease
biology.organism_classification
DNA
Viral

Immunology
business
Zdroj: American Journal of Transplantation. 9:374-381
ISSN: 1600-6135
DOI: 10.1111/j.1600-6143.2008.02501.x
Popis: The effect of herpesvirus co-infections (HHV-6, HHV-7) on cytomegalovirus (CMV) disease and its response to therapy is unknown. We prospectively analyzed herpesvirus co-infections in transplant recipients with CMV disease. All patients received 3 weeks of antiviral therapy. Samples were collected at baseline (day 0) and then day 3, 7, 14 and 21 poststart of therapy. Viral load testing for CMV, HHV-6 and HHV-7 was done using quantitative PCR assays in 302 patients of whom 256 had documented symptomatic CMV viremia. In this subset, day 0 HHV-6 co-infection was present in 23/253 (9.1%) and HHV-7 in 17/253 (6.7%). Including those positive at any time point raised the prevalence to 79/256 (30.9%) for HHV-6 and 75/256 (29.3%) for HHV-7. Viral co-infection did not influence the response of CMV disease to antiviral therapy. Baseline CMV viral loads, time to eradication and risk of recurrence were similar in patients with and without HHV-6 or HHV-7 co-infection. Ganciclovir and valganciclovir had no clear effect on HHV-6 and HHV-7 viremia. In conclusion, herpesvirus co-infections are common in patients with CMV disease but with standard antiviral therapy, no clear clinical effects are discernable. Routine monitoring for viral co-infection in patients with CMV disease is not indicated.
Databáze: OpenAIRE